The Endocrine Society Endorses Recommendation To Curtail Use Of Commonly Used Antithyroid Drug For Children

Main Category: Endocrinology
Also Included In: Pediatrics / Children's Health
Article Date: 19 Apr 2009 - 1:00 PDT

email to a friend   printer friendly   opinions  

In their letter to the editor published in the April 9, 2009 issue of the New England Journal of Medicine¹, Scott A. Rivkees, M.D. of Yale University School of Medicine and Donald R. Mattison, M.D. of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, highlight concerns about potential severe liver disease in children from the commonly used antithyroid drug, propylthiouracil (PTU) an adverse effect not seen with the other thionamide derivative, methimazole.

On the basis of several lines of evidence and frequency estimates some of which were presented at the National Institute of Child Health and Human Development (NICHD) workshop "Hepatic Toxicity Following Treatment for Pediatric Graves' Disease" on October 28, 2008 2, these authors suggest that PTU no longer be used as first-line treatment for Graves' disease in the pediatric age range.

The Endocrine Society endorses this recommendation. Despite the relative rarity of Graves' disease in the young, children and adolescents account for as many as 13 of 42 cases of serious PTU-related liver failure reported to date in the medical literature and a similar disproportionate number (4 of 13) of those requiring liver transplant for this indication between 1990-20023.

Although precise numbers are not known with certainty, it can be estimated that there are 4,000 children treated each year for Graves' disease in the United States. If 40 percent are treated with PTU, then as many as 1-2 children a year could develop severe liver disease, with some requiring a liver transplant or potentially suffering a fatal outcome.

Even one excess death is too many if it can be prevented. The Society therefore suggests that until data from more thorough prospective studies or peer-reviewed retrospective studies become available, it would seem reasonable to use methimazole preferentially in the pediatric population.

1. Rivkees SA, Mattison DR Ending propylthiouracil-induced liver failure in children. N Engl J Med 2009;360:1574-5

2. Eunice Kennedy Shriver National Institute of Child Health and Human Development./ Hepatic Toxicity Following Treatment for Pediatric Graves' Disease Meeting: October 28,2008. Conference Proceeding. http://bpca.nichd.nih.gov/outreach/index.cfm

3. Russo MW, Galanko JA, Shrestha R et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transplantation 2004;10:1018-23

Founded in 1916, The Endocrine Society is the world's oldest, largest, and most active organization devoted to research on hormones and the clinical practice of endocrinology. Today, The Endocrine Society's membership consists of over 14,000 scientists, physicians, educators, nurses and students in more than 80 countries. Together, these members represent all basic, applied, and clinical interests in endocrinology. The Endocrine Society is based in Chevy Chase, Md. To learn more about the Society, and the field of endocrinology, visit our web site at http://www.endo-society.org.

Source
The Endocrine Society

• Additional
• References
• Citations